Today: 27 June 2026
Nvidia stock price rises after-hours on report of $30 billion OpenAI investment as earnings loom
20 February 2026
2 mins read

Nvidia stock price rises after-hours on report of $30 billion OpenAI investment as earnings loom

New York, Feb 20, 2026, 16:50 ET — Trading after the bell

  • Nvidia shares were recently up around 1% in after-hours trading following reports the company is nearing a $30 billion investment in OpenAI.
  • Nvidia’s Feb. 25 results are now the reference point for investors watching AI chip demand and tracking what customers are willing to spend.
  • March’s GTC conference is on the radar too, with CEO Jensen Huang set to deliver the keynote, drawing traders’ attention.

Shares of NVIDIA Corporation (NVDA.O) picked up roughly 1% in after-hours action on Friday, most recently at $189.82, following a Reuters report that the chipmaker is nearing a $30 billion investment in OpenAI. That stake would come as part of a funding round in which OpenAI is seeking over $100 billion, potentially pushing its valuation to around $830 billion. Nvidia gave no comment, according to Reuters.

Nvidia’s fiscal fourth-quarter and full-year results drop after the bell on Feb. 25. The company plans a 5 p.m. ET conference call that same day, with written CFO commentary coming soon after the numbers hit.

Nvidia has become the go-to AI proxy for investors, but a bumpy kickoff to 2026 has thrown some cold water on the AI trade. Markets are also digesting the U.S. Supreme Court’s move to overturn President Donald Trump’s broad tariffs. “It’s hard for Nvidia to surprise when everyone expects it to surprise,” Empower’s chief investment strategist Marta Norton told Reuters. Nick Giorgi at Alpine Macro thinks Nvidia CEO Jensen Huang “has to come out and show his confidence” in customers. Reuters

Nvidia commands a hefty 7.8% slice of the S&P 500 and is forecast to deliver a 71% jump in earnings per share, with revenue pegged at $65.9 billion for the quarter, according to LSEG data. Next fiscal year’s EPS projections are all over the map—from $6.28 up to $9.68—a range Melissa Otto at S&P Global Visible Alpha labeled “significant.” The S&P 500 software and services index has dropped roughly 20% this year. King Lip at BakerAvenue Wealth Management thinks the selloff has been “overdone,” though he points out some firms will need to “adapt and innovate.” Kitco

Nvidia’s possible investment in OpenAI would further cement its relationship with a key buyer that relies on its chips for AI training and deployment. The move highlights a tightening web within the AI supply chain, where chip producers, cloud providers, and AI model developers increasingly depend on one another—not just for hardware, but also for funding.

But that sets up more questions heading into next week’s earnings call. Investors will be watching to see how Nvidia talks about demand from its top customers—and if tighter scrutiny in the ecosystem shifts the company’s take on cash or risk management.

Options traders are positioning for volatility tied to the report, with the at-the-money “straddle” for Feb. 27 expiry pricing in a move of roughly 7%—more than double the 3.2% median swing from the last 10 earnings periods, according to MarketWatch. MarketWatch

It’s a double-edged sword. Nvidia could deliver strong results, but if its forecast or commentary doesn’t impress, shares can slip—particularly if investors start doubting how long AI spending by its biggest customers will hold up.

The field isn’t idle. Advanced Micro Devices and Broadcom, for example, are pushing into the data-center expansion too, offering their own accelerators and networking hardware. That’s left investors watching to see if Nvidia can hold onto pricing power and manage supply as the cycle plays out.

Nvidia’s GTC conference kicks off in San Jose from March 16 to 19, and CEO Jensen Huang is on tap for the keynote address March 16.

Traders are looking at Monday to see how Nvidia shares react after the OpenAI investment headlines. The wider AI trade? Still a question mark as the week kicks off. Eyes on Feb. 25 for the next major trigger — that’s when results hit, and Huang’s comments on the call follow.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

Lucid (NASDAQ:LCID) jumps, adding about $312 million after $158 million cost plan

27 June 2026
Lucid surged 15.6% Friday, adding $312 million in equity value—almost double the $158 million in annualized savings from this week’s restructuring plan that cut 18% of its U.S. workforce. Friday’s volume equaled 54% of reported short interest, but the rally outpaced cost-cutting fundamentals, leaving less room for further gains based solely on headcount cuts.
Court ruling on student loans hits private lenders’ health grad loan push

Court ruling on student loans hits private lenders’ health grad loan push

27 June 2026
Judge blocks narrow “professional degree” rule, letting more health-care grad students keep higher federal loan caps; $7.87B in 2023-24 borrowing above new limits remains in federal market, trimming but not eliminating the $4.5B-$5B annual private loan growth Sallie Mae projected from Grad PLUS loan cuts.
GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines
Previous Story

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop